ABOUT US
About HLB
Greeting
History
Location
GROUP
Pharma·Bio
Ship ·Plant ·Energy
Life · Health · Leisure
Finance
BUSINESS
Pharma·Bio
cytotoxic antineoplastic drug
targeted therapy
immunotherapy
Healthcare
Special ship
ESG
EHS
EHS경영
친환경 제품 및 서비스
인증 및 수상
CSR
Human resources
인재육성 제도
복리후생
직원안전 및 보건
핵심고용지표
Governance
주주
이사회
정관
기타
Initiative
ESG Report
IR
Stock Index
Official Notice
PR
Press
Library
CAREERS
Recruiting
ENG
Korean
English
home
Title + Content
Title+Content
Title
Content
Search
Number
Title
Author
Date
48
Rivoceranib approved for phase 3 clinical trial as first-line lung cancer treatment
admin
47
Doctor William Hearl appointed as the Director of HLB
admin
46
Elevar Therapeutics announces enrollment of the first patient in a pivotal trial for the treatment of Adenoid Cystic Cancer (AC
admin
45
HLB requests marketing authorization for second-line liver cancer for Rivoceranib
admin
44
HLB's acquisiton of Rivoceranib's global rights
admin
43
HLB takes over Immunomic Therapeutics
admin
42
HLB receives Pre-NDA Meeting Minutes from FDA
admin
2019.11.25
41
HLB initiates administration to the first patient in clinical combination study of Colorectal Cancer
admin
2019.11.20
40
HLB completes Pre-NDA meeting with FDA
admin
2019.10.25
39
HLB, Elevar agree to triangular merger deal to speed up Rivoceranib development
admin
2019.10.16
<<
<
11
12
13
14
15